Kurs
-8,96%
Kalender
| Tid* | ||
| 2025-02-19 | 13:00 | Bokslutskommuniké 2024 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-10 | - | Extra Bolagsstämma 2024 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | Split BGBIO 100:1 |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-24 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-22 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-22 | - | Årsstämma |
| 2023-04-21 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-15 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-29 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2022-01-06 | - | Extra Bolagsstämma 2022 |
| 2021-11-16 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2021-03-19 | - | Årsstämma |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-12-09 | - | Extra Bolagsstämma 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-19 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-17 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2020-03-16 | - | Årsstämma |
| 2020-02-11 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-19 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-14 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2019-03-13 | - | Årsstämma |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-11-13 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-14 | - | Årsstämma |
| 2018-03-09 | - | Extra Bolagsstämma 2018 |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2017-03-22 | - | Årsstämma |
| 2016-06-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2016-06-21 | - | Årsstämma |
| 2015-06-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2015-06-22 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Issuer name: BerGenBio ASA
Ex. date: 30 May 2024
Type of corporate action: Reverse share split
Reverse split ratio: One hundred (100) old shares give one (1) new share.
New par value per share: NOK 10
New ISIN: NO 001 3251173
New number of shares outstanding: 39,087,116
For further information, please contact:
Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
This information is published in accordance with the requirements of the Continuing Obligations pursuant to Oslo Rule Book II.